Table 1.
Literature review of cases of LEMS treatment with ICI.
| Case |
Author name (year) |
Age |
Sex |
Pathology |
LEMS therapy |
ICI |
Anti-P/Q-type VGCC antibodies |
Symptom |
Tumor response |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Pre-treatment | Post-Treatment | |||||||||
| 1 | Dohrn et al. (2020) | 62 | F | MCC | 3,4-diaminopyridine, pyridostigmine, IVIG | Avelumab | 387.6 | NA | Worsen | CR |
| 2 | Sakaguchi et al. (2022) | 56 | M | SCLC | None | Atezolizumab | >30 | NA | Improvement | PR |
| 3 | Green et al. (2022) | 67 | M | MCC | 3,4-diaminopyridine, pyridostigmine | Avelumab | 65.2 | ND | Improvement | PR |
| 4 | Machiyama et al. (2023) | 62 | F | SCLC | pyridostigmine | Durbalumab | 1419.2 | 263.5 | Improvement | PR |
| 5 | Crrent case | 65 | M | SCLC | None | Durbalumab | >250 | 130 | Improvement | PR |
LEMS: Lambert-Eaton myasthenic syndrome, ICI: Immune checkpoint inhibitor, MCC: Merkel cell carcinoma, SCLC: Small-cell lung carcinoma, IVIG: Intravenous immunoglobulin, NA: Not available, ND: Not detected, CR: Complete response, PR: Partial response.